Tysabri gets panel nod to return to market
An FDA advisory panel ruled unanimously today that Biogen Idec’s multiple sclerosis drug Tysabri should return to the market with ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.